Inhibitors of BRAF dimers using an allosteric site

BRAF kinase, a critical effector of the ERK signaling pathway, is hyperactivated in many cancers. Oncogenic BRAF(V600E) signals as an active monomer in the absence of active RAS, however, in many tumors BRAF dimers mediate ERK signaling. FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotto-Rios, Xiomaris M., Agianian, Bogos, Gitego, Nadege, Zacharioudakis, Emmanouil, Giricz, Orsi, Wu, Yang, Zou, Yiyu, Verma, Amit, Poulikakos, Poulikos I., Gavathiotis, Evripidis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462985/
https://www.ncbi.nlm.nih.gov/pubmed/32873792
http://dx.doi.org/10.1038/s41467-020-18123-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462985/
https://www.ncbi.nlm.nih.gov/pubmed/32873792
http://dx.doi.org/10.1038/s41467-020-18123-2

Ejemplares similares